

1 Transcatheter Aortic Valve Replacement Use in Young Patients Before and After Low-Risk

2 Indication Approval

3

4 Authors: Christina Waldron BS¹, Luigi Pirelli MD², Isaac George MD², Hiroo Takayama MD

5 PhD², Arnar Geirsson MD², Roland Assi MD MMS¹, Makoto Mori MD PhD³

6

7 ¹Division of Cardiac Surgery, Yale University School of Medicine, New Haven, CT

8 ²Division of Cardiac, Thoracic and Vascular Surgery, Columbia University, NY, New York

9 ³Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT

10

11 IRB protocol number: 2000028791, approved on 9/2/23

12

13 Disclosures:

14 Dr. Geirsson receives a consulting fee from Medtronic and Edwards Lifesciences.

15 All other authors have nothing to disclose.

16

17 Corresponding author: Makoto Mori, MD PhD

18 Division of Cardiac Surgery

19 Yale School of Medicine

20 BB204, 330 Cedar Street

21 P.O. Box 208039, 06510

22 New Haven, CT

23 Business phone: 203-785-6214

24 Fax: 203-785-3346

25 Email: makoto.mori@yale.edu

26

27 Word Count (1077/1200)

28 **Abstract**

29 Transcatheter aortic valve replacement (TAVR) use in young patients has recently increased
30 following FDA approval for use in low-risk patients. How TAVR use among young patients may
31 have accelerated in the interval between the FDA approval and the guideline publication remain
32 unknown. We sought to characterize the national trends in aortic valve replacement (AVR)
33 among young patients before and after the low-risk indication approval. Using the National
34 Inpatient Sample data, we conducted a cross-sectional study of patients younger than 65 years of
35 age who underwent TAVR, SAVR, or Ross operations between January 1, 2016, and February
36 29, 2020. We compared in-hospital mortality before and after the low-risk indication approval to
37 infer whether the expansion occurred among lower-risk strata within the TAVR group in relation
38 to SAVR. We identified 106,340 AVRs, including 13,095 TAVR (12.3%), 63,620 bioprosthetic
39 SAVR (59.8%), 28,370 mechanical SAVR (26.7%), and 1,255 Ross (1.2%). The mean age was
40 54 (10.9), including 32,775 (30.8%) women. Before and after the low-risk approval, the TAVR
41 share increased at 0.25 (0.03%) and 0.60 (0.09%) per month, respectively (interaction term p-
42 value <0.001). Expansion of TAVR use among young patients around the time of FDA approval
43 in low surgical risk patients serves as a case study to highlight the potential importance of
44 specifying the indicated age group in future FDA approvals of transcatheter valve intervention
45 devices.

47 **Introduction**

48 Transcatheter aortic valve replacement (TAVR) use in young patients has recently
49 increased¹. The U.S. Food and Drug Administration (FDA) approval of balloon-expanded and
50 self-expandable TAVR devices for low-risk patients did not specify the indicated age group,

51 although the participants in both pivotal trials, PARTNER 3 and Evolut low-risk trials, were old
52 at a mean age of 73^{2,1}. The high-risk nature of TAVR explant and unknown long-term valve
53 durability are important considerations related to TAVR use among young patients with expected
54 longevity³. While the current U.S. guideline recommends surgical aortic valve replacement
55 (SAVR) in low-risk patients younger than 65⁴, the first guideline specifying such age threshold
56 was published in 2020, 2 years after the first FDA approval of TAVR for low-risk patients. How
57 TAVR use among young patients may have accelerated in the interval between the FDA approval
58 and the guideline publication remain unknown.

59 Numerous trials are underway to evaluate transcatheter valve repair and replacement in
60 non-aortic positions. With expected data lag and guideline publication lag accounting for the
61 device durability and long-term outcomes, examining the rapidity of TAVR use expansion in
62 young patients around the time of low-risk TAVR approval may serve as a case study to inform
63 the nuances of future FDA approval of devices currently undergoing trials⁵.

64 To understand how the low-risk indication approval may have accelerated TAVR
65 utilization nationally in this age group, we characterized the national trends in aortic valve
66 replacement (AVR) among young patients before and after the low-risk indication approval.

67

68 **Methods**

69 Using the National Inpatient Sample (NIS) data, a 20% stratified sample of all inpatient
70 discharges from US non-federal hospitals, we conducted a cross-sectional study of patients
71 younger than 65 years of age who underwent TAVR, SAVR, or Ross operations between January
72 1, 2016, and February 29, 2020 (the latest available year, up to the COVID-19 stay-at home
73 order). Operations and aortic valve pathology were defined using the *International Classification*

74 *of Diseases, 10th revision (ICD-10) (Supplemental Table). Patients with endocarditis were*
75 *excluded. Difference-in-difference analysis estimated the association between the low-risk*
76 *indication approval on August 16, 2018 (cutoff on September 1, 2018) and the change in the*
77 *monthly percent TAVR share among all AVRs as a continuous variable (Supplemental Methods).*
78 *We compared in-hospital mortality before and after the low-risk indication approval to infer*
79 *whether the expansion occurred among lower-risk strata within the TAVR group in relation to*
80 *SAVR.*

81 We used the ‘survey’ R package, applied the hospital discharge weight variable in the
82 NIS dataset to estimate the total national volume of index operations, and performed the chi-
83 squared test, accounting for the sampled nature of the dataset. Difference-in-difference model
84 was specified with the outcome being the monthly percent of TAVR share among all AVRs, with
85 the covariates of the month as a nominal variable and a pre/post indicator of before and after
86 September 1, 2018. An interaction term was added as the product of the month and pre/post
87 indicator variable.

88 Analyses were performed in R version 4.2.2 (R Foundation). All P values were 2-sided,
89 with <0.05 denoting statistical significance. This study was approved by the Yale Institutional
90 Review Board. Informed consent was waived because the data were deidentified.

91

92 **Results**

93 We identified 106,340 AVRs, including 13,095 TAVR (12.3%), 63,620 bioprosthetic
94 SAVR (59.8%), 28,370 mechanical SAVR (26.7%), and 1,255 Ross (1.2%). The mean age was
95 54±10.9, including 32,775 (30.8%) women. The proportion of TAVR increased from 6.9% in

96 2016 to 22.4% in 2020. The shares of mechanical SAVR remained stable from 29.8% to 26%,
97 while bioprosthetic SAVR decreased from 62.2% to 50.9%.

98 Before and after the low-risk approval, the TAVR share increased at $0.25\pm 0.03\%$ and
99 $0.60\pm 0.09\%$ per month, respectively (interaction term p -value < 0.001 , Figure 1A). Among
100 patients undergoing TAVR, in-hospital mortality was 2.4% before and 1.1% after the approval
101 ($p=0.015$, Figure 1B). Among patients undergoing bioprosthetic SAVR, in-hospital mortality
102 was 2.5% before and 2% after ($p=0.1$), and for mechanical SAVR, in-hospital mortality was 3%
103 before and 3.5% after the approval ($p=0.28$). In-hospital mortality for patients undergoing the
104 Ross procedure was 1.9% before and 1.1% after approval ($p=0.67$).

105 Among patients younger than 50, TAVR share increased from 3.1% in 2016 to 6.7% in
106 2020. SAVR was increasingly performed for congenital pathology, including bicuspid valve
107 (18% of SAVR in 2016 to 29% in 2020), while the pathology composition remained stable for
108 TAVR.

109

110 **Discussion**

111 We demonstrated that TAVR use in patients younger than 65 was increasing prior to the
112 FDA approval for low-risk indication, and accelerated after the FDA approval, more than
113 doubling the rate of monthly increase. The share of TAVR among all AVRs in this age group
114 tripled between 2016 and 2020 preceding the publication of the first guideline specifying age
115 threshold for low-risk TAVR. Significantly lower in-hospital mortality after the approval was
116 observed only among TAVR patients, suggesting that the TAVR use in this young age group
117 expanded towards lower-risk patients. These data suggest the importance of regulatory bodies to

118 delineate the indicated age group for novel indication transcatheter valve devices, as the first
119 guidance specifying the age threshold lagged by 2 years following this FDA approval.

120 Considerations surrounding the patient age is relevant, because low risk is not
121 synonymous to young age in prosthetics with age-dependent durability. Yet, the accelerated
122 increase in TAVR share among young patients around the time of the FDA approval may reflect
123 the public's reception of the low-risk approval. Ongoing trials on moderate or asymptomatic
124 severe aortic stenosis may follow similar trend⁶. Similarly, transcatheter edge-to-edge mitral
125 repair is being compared with surgical mitral valve repair⁷. The trial population will likely be
126 old, with the inclusion criteria of older than 65, which is above the national mean of those
127 undergoing surgical MV repair for degenerative disease⁷. With less competing risks, the long-
128 term impact of residual mitral regurgitation and the impact of device durability are likely more
129 pronounced in younger patients. As novel devices expand in indications, the momentum of
130 'indication creep'⁵ may be balanced with a clear age threshold for indication by the regulatory
131 bodies.

132 The NIS is claims-based and lacks granular risk characteristics. Therefore, we used in-
133 hospital mortality as a surrogate of patient risk profile. Valve pathology diagnosis was missing in
134 15%.

135

136 **Conclusion**

137 Expansion of TAVR use among young patients around the time of the FDA approval of
138 balloon-expandable TAVR in low surgical risk patients serves as a case study to highlight the
139 potential importance of specifying the indicated age group in future FDA approvals of

140 transcatheter valve intervention devices that may have age-dependent durability and unknown
141 long-term implications.

142


143

144 **References**


- 145 1. Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National Trends
146 in TAVR and SAVR for Patients With Severe Isolated Aortic Stenosis. *Journal of the*
147 *American College of Cardiology*. 2022;80(21):2054-2056.
148 doi:doi:10.1016/j.jacc.2022.08.787
- 149 2. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement
150 with a Balloon-Expandable Valve in Low-Risk Patients. *New England Journal of*
151 *Medicine*. 2019;380(18):1695-1705. doi:10.1056/NEJMoa1814052
- 152 3. Hawkins RB, Deeb GM, Sukul D, et al. Redo Surgical Aortic Valve Replacement
153 After Prior Transcatheter Versus Surgical Aortic Valve Replacement. *JACC:*
154 *Cardiovascular Interventions*. 2023/04/24/ 2023;16(8):942-953.
155 doi:<https://doi.org/10.1016/j.jcin.2023.03.015>
- 156 4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the
157 Management of Patients With Valvular Heart Disease: A Report of the American College
158 of Cardiology/American Heart Association Joint Committee on Clinical Practice
159 Guidelines. *Circulation*. 2021;143(5):e72-e227. doi:doi:10.1161/CIR.0000000000000923
- 160 5. Goel SS, Reardon MJ. Indication Creep in Transcatheter Aortic Valve
161 Implantation—Data or Desire? *JAMA Cardiology*. 2023;8(6):519-520.
162 doi:10.1001/jamacardio.2023.0674
- 163 6. PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance
164 or TAVR (PROGRESS). ClinicalTrials.gov Identifier: NCT04889872. Updated April 29,
165 2024. Accessed May 19, 2024. <https://classic.clinicaltrials.gov/ct2/show/NCT04889872>.
- 166 7. McCarthy PM, Whisenant B, Asgar AW, et al. Percutaneous MitraClip Device or
167 Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are
168 Candidates for Surgery: Design and Rationale of the REPAIR MR Trial. *Journal of the*
169 *American Heart Association*. 2023;12(4):e027504. doi:doi:10.1161/JAHA.122.027504
170

171 Figure 1: Annual Trends of Transcatheter Aortic Valve Replacement Shares and AVR Mortality
172 Among Patients < 65

A. Change in the Rate of TAVR Share Among Patients < 65



B. Quarterly In-Hospital Mortality Trend Among Patients < 65 Undergoing AVR



173
174 This figure shows a change in the rate of TAVR share among patients < 65 years of age before
175 and after the first low-risk indication approval in August 2018 (panel A) and the quarterly in-
176 hospital mortality trends among patients < 65 undergoing SAVR and TAVR (panel B). Red lines
177 are linear regression lines fitted to the TAVR share before and after September 1, 2018. AVR:
178 Aortic valve replacement; SAVR: Surgical aortic valve replacement; TAVR: Transcatheter aortic
179 valve replacement.

180

181

182 Supplemental Table: ICD Codes for Procedures and Aortic Pathology Etiologies

183

Procedure or Aortic Pathology	ICD Code
TAVR	02RF37Z, 02RF38Z, 02RF3JZ, 02RF3KZ
Bioprosthetic/biologic SAVR	02RF07Z, 02RF08N, 02RF08Z, 02RF0KZ, 02RF48N, 02RF48Z, 02RF4KZ, 02RF47Z
Mechanical SAVR	02RF0JZ, 02RF4JZ
Ross Operation ¹	Defined as simultaneous use of biological AVR and replacement of pulmonary valve with tissue graft, including homograft
Biologic AVR	02RF07Z, 02RF08Z, 02RF0KZ
Replacement of pulmonary Valve with tissue graft, including homograft	02RH07Z, 02RH08Z, 02RH0KZ, 02RH47Z
Infective Endocarditis	I33, I38, I339, T826, B376, I39, I398, I423, I091, I011, A3951, A3282, B3321, A5483
Aortic stenosis	I350
Aortic insufficiency	I351
Mixed aortic stenosis and insufficiency	I352
Congenital AI/AS including BAV	Q2383, Q231, Q230

184

185 AI: Aortic Insufficiency; AS: Aortic Stenosis; BAV: Bicuspid Aortic Valve; SAVR: Surgical

186 Aortic Valve Replacement; TAVR: Transcatheter Aortic Valve Replacement.

187

- 188 1. El-Hamamsy I, Toyoda N, Itagaki S, et al. Propensity-Matched Comparison of the Ross
189 Procedure and Prosthetic Aortic Valve Replacement in Adults. *J Am Coll Cardiol*.
190 2022;79:805-815.